Total and high molecular weight (HMW) adiponectin levels and measures of glucose and lipid metabolism following pioglitazone treatment in a randomized placebo-controlled study in polycystic ovary syndrome

Clinical Endocrinology

Volumn 68, Issue 2, 2008, Pages 165-174

  Glintborg, Dorte ^a,c   Frystyk, Jan ^b   Højlund, Kurt ^a   Andersen, Kristian Kjær ^b   Henriksen, Jan Erik ^a   Hermann, Anne Pernille ^a   Hagen, Claus ^a   Flyvbjerg, Allan ^b   Andersen, Marianne ^a  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

^c NONE   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; GLUCOSE; LIPID; PIOGLITAZONE; PLACEBO;

ANKLE EDEMA; ANXIETY; ARTICLE; CALORIMETRY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DRUG EFFECT; FEMALE; GLUCOSE METABOLISM; HUMAN; LIPID METABOLISM; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT;

ADIPONECTIN; BLOOD GLUCOSE; FASTING; FEMALE; GLUCOSE CLAMP TECHNIQUE; HUMANS; LIPID METABOLISM; PLACEBOS; POLYCYSTIC OVARY SYNDROME; THIAZOLIDINEDIONES;

EID: 38049177902     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2007.03015.x     Document Type: Article

References (55)

1. The Rotterdam ESHRE/ASRM-sponsored PCOS Consensus Workshop Group (2004) Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertility and Sterility, 81, 19 25.
2. Ehrmann, D.A., Barnes, R.B., Rosenfield, R.L., Cavaghan, M.K. Imperial, J. (1999) Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care, 22, 141 146.
3. Glintborg, D., Henriksen, J.E., Andersen, M., Hagen, C., Hangaard, J., Rasmussen, P.E., Schousboe, K. Hermann, A.P. (2004) The prevalence of endocrine diseases and abnormal glucose tolerance tests in 340 Caucasian, premenopausal women with hirsutism as primary diagnosis. Fertility and Sterility, 82, 1570 1579.
4. Douchi, T., Ijuin, H., Nakamura, S., Oki, T., Yamamoto, S. Nagata, Y. (1995) Body fat distribution in women with polycystic ovary syndrome. Obstetrics and Gynecology, 86, 516 519.
5. Kirchengast, S. Huber, J. (2001) Body composition characteristics and body fat distribution in lean women with polycystic ovary syndrome. Human Reproduction, 16, 1255 1260.
6. Fasshauer, M. Paschke, R. (2003) Regulation of adipocytokines and insulin resistance. Diabetologia, 46, 1594 1603.
7. Diez, J.J. Iglesias, P. (2003) The role of the novel adipocyte-derived hormone adiponectin in human disease. European Journal of Endocrinology, 148, 293 300.
8. Spranger, J., Mohlig, M., Wegewitz, U., Ristow, M., Pfeiffer, A.F., Schill, T., Schlosser, H.W., Brabant, G. Schofl, C. (2004) Adiponectin is independently associated with insulin sensitivity in women with polycystic ovary syndrome. Clinical Endocrinology, 61, 738 746.
9. Ardawi, M.S. Rouzi, A.A. (2005) Plasma adiponectin and insulin resistance in women with polycystic ovary syndrome. Fertility and Sterility, 83, 1708 1716.
10. Chen, M.B., McAinch, A.J., Macaulay, S.L., Castelli, L.A., O'Brien, P.E., Dixon, J.B., Cameron-Smith, D., Kemp, B.E. Steinberg, G.R. (2005) Impaired activation of AMP-kinase and fatty acid oxidation by globular adiponectin in cultured human skeletal muscle of obese type 2 diabetics. Journal of Clinical Endocrinology and Metabolism, 90, 3665 3672.
11. Yamauchi, T., Kamon, J., Minokoshi, Y., Ito, Y., Waki, H., Uchida, S., Yamashita, S., Noda, M., Kita, S., Ueki, K., Eto, K., Akanuma, Y., Froguel, P., Foufelle, F., Ferre, P., Carling, D., Kimura, S., Nagai, R., Kahn, B.B. Kadowaki, T. (2002) Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nature Medicine, 8, 1288 1295.
12. Højlund, K., Frystyk, J., Levin, K., Flyvbjerg, A., Wojtaszewski, J.F. Beck-Nielsen, H. (2006) Reduced plasma adiponectin concentrations may contribute to impaired insulin activation of glycogen synthase in skeletal muscle of patients with type 2 diabetes. Diabetologia, 49, 1283 1291.
13. Stefan, N., Vozarova, B., Funahashi, T., Matsuzawa, Y., Weyer, C., Lindsay, R.S., Youngren, J.F., Havel, P.J., Pratley, R.E., Bogardus, C. Tataranni, P.A. (2002) Plasma adiponectin concentration is associated with skeletal muscle insulin receptor tyrosine phosphorylation, and low plasma concentration precedes a decrease in whole-body insulin sensitivity in humans. Diabetes, 51, 1884 1888.
14. Salmenniemi, U., Zacharova, J., Ruotsalainen, E., Vauhkonen, I., Pihlajamaki, J., Kainulainen, S., Punnonen, K. Laakso, M. (2005) Association of adiponectin level and variants in the adiponectin gene with glucose metabolism, energy expenditure, and cytokines in offspring of type 2 diabetic patients. Journal of Clinical Endocrinology and Metabolism, 90, 4216 4223.
15. Yokoyama, H., Emoto, M., Mori, K., Araki, T., Teramura, M., Koyama, H., Shoji, T., Inaba, M. Nishizawa, Y. (2006) Plasma adiponectin level is associated with insulin-stimulated nonoxidative glucose disposal. Journal of Clinical Endocrinology and Metabolism, 91, 290 294.
16. Glintborg, D., Andersen, M., Hagen, C., Frystyk, J., Hulstrom, V., Flyvbjerg, A. Hermann, A.P. (2006) Evaluation of metabolic risk markers in polycystic ovary syndrome (PCOS). Adiponectin, ghrelin, leptin and body composition in hirsute PCOS patients and controls. European Journal of Endocrinology, 155, 337 345.
17. Sepilian, V. Nagamani, M. (2005) Adiponectin levels in women with polycystic ovary syndrome and severe insulin resistance. Journal of the Society for Gynecologic Investigation, 12, 129 134.
18. Sieminska, L., Marek, B., Kos-Kudla, B., Niedziolka, D., Kajdaniuk, D., Nowak, M. Glogowska-Szelag, J. (2004) Serum adiponectin in women with polycystic ovarian syndrome and its relation to clinical, metabolic and endocrine parameters. Journal of Endocrinological Investigation, 27, 528 534.
19. Carmina, E., Orio, F., Palomba, S., Cascella, T., Longo, R.A., Colao, A.M., Lombardi, G. Lobo, R.A. (2005) Evidence for altered adipocyte function in polycystic ovary syndrome. European Journal of Endocrinology, 152, 389 394.
20. Vrbikova, J., Dvorakova, K., Hill, M., Vcelak, J., Stanicka, S., Vankova, M., Sramkova, D., Vondra, K., Bendlova, B. Starka, L. (2005) Determinants of circulating adiponectin in women with polycystic ovary syndrome. Gynecologic and Obstetric Investigation, 60, 155 161.
21. Whitehead, J.P., Richards, A.A., Hickman, I.J., Macdonald, G.A. Prins, J.B. (2006) Adiponectin - a key adipokine in the metabolic syndrome. Diabetes, Obesity and Metabolism, 8, 264 280.
22. Lara-Castro, C., Luo, N., Wallace, P., Klein, R.L. Garvey, W.T. (2006) Adiponectin multimeric complexes and the metabolic syndrome trait cluster. Diabetes, 55, 249 259.
23. Hara, K., Horikoshi, M., Yamauchi, T., Yago, H., Miyazaki, O., Ebinuma, H., Imai, Y., Nagai, R. Kadowaki, T. (2006) Measurement of the high-molecular weight form of adiponectin in plasma is useful for the prediction of insulin resistance and metabolic syndrome. Diabetes Care, 29, 1357 1362.
24. Aso, Y., Yamamoto, R., Wakabayashi, S., Uchida, T., Takayanagi, K., Takebayashi, K., Okuno, T., Inoue, T., Node, K., Tobe, T., Inukai, T. Nakano, Y. (2006) Comparison of serum high-molecular weight (HMW) adiponectin with total adiponectin concentrations in type 2 diabetic patients with coronary artery disease using a novel enzyme-linked immunosorbent assay to detect HMW adiponectin. Diabetes, 55, 1954 1960.
25. Nakashima, R., Kamei, N., Yamane, K., Nakanishi, S., Nakashima, A. Kohno, N. (2006) Decreased total and high molecular weight adiponectin are independent risk factors for the development of type 2 diabetes in Japanese-Americans. Journal of Clinical Endocrinology and Metabolism, 91, 3873 3877.
26. Lord, J.M., Flight, I.H. Norman, R.J. (2003) Insulin-sensitising drugs (metformin, troglitazone, rosiglitazone, pioglitazone, D-chiro-inositol) for polycystic ovary syndrome. Cochrane Database of Systematic Reviews, 3, CD003053.
27. Lord, J.M., Flight, I.H. Norman, R.J. (2003) Metformin in polycystic ovary syndrome: systematic review and meta-analysis. British Medical Journal, 327, 951 953.
28. Mayerson, A.B., Hundal, R.S., Dufour, S., Lebon, V., Befroy, D., Cline, G.W., Enocksson, S., Inzucchi, S.E., Shulman, G.I. Petersen, K.F. (2002) The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes. Diabetes, 51, 797 802.
29. Miyazaki, Y., Mahankali, A., Matsuda, M., Mahankali, S., Hardies, J., Cusi, K., Mandarino, L.J. DeFronzo, R.A. (2002) Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. Journal of Clinical Endocrinology and Metabolism, 87, 2784 2791.
30. Boden, G., Cheung, P., Mozzoli, M. Fried, S.K. (2003) Effect of thiazolidinediones on glucose and fatty acid metabolism in patients with type 2 diabetes. Metabolism, 52, 753 759.
31. Bouskila, M., Pajvani, U.B. Scherer, P.E. (2005) Adiponectin: a relevant player in PPARgamma-agonist-mediated improvements in hepatic insulin sensitivity? International Journal of Obesity (London), 29 (Suppl. 1 S17 S23.
32. Bodles, A.M., Banga, A., Rasouli, N., Ono, F., Kern, P.A. Owens, R.J. (2006) Pioglitazone increases secretion of high-molecular-weight adiponectin from adipocytes. American Journal of Physiology. Endocrinology and Metabolism, 291, E1100 E1105.
33. Pajvani, U.B., Hawkins, M., Combs, T.P., Rajala, M.W., Doebber, T., Berger, J.P., Wagner, J.A., Wu, M., Knopps, A., Xiang, A.H., Utzschneider, K.M., Kahn, S.E., Olefsky, J.M., Buchanan, T.A. Scherer, P.E. (2004) Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity. Journal of Biological Chemistry, 279, 12152 12162.
34. Tonelli, J., Li, W., Kishore, P., Pajvani, U.B., Kwon, E., Weaver, C., Scherer, P.E. Hawkins, M. (2004) Mechanisms of early insulin-sensitizing effects of thiazolidinediones in type 2 diabetes. Diabetes, 53, 1621 1629.
35. Glintborg, D., Støving, R.K., Hagen, C., Hermann, A.P., Frystyk, J., Veldhuis, J.D, Flyvbjerg, A. Andersen, M. (2005) Pioglitazone treatment increases spontaneous growth hormone (GH) secretion and stimulated GH levels in polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism, 90, 5605 5612.
36. Glintborg, D., Hermann, A.P., Andersen, M., Hagen, C., Beck-Nielsen, H., Veldhuis, J.D. Henriksen, J.E. (2006) Effect of pioglitazone on glucose metabolism and luteinizing hormone secretion in women with polycystic ovary syndrome. Fertility and Sterility, 86, 385 397.
37. Rosenfield, R.L. (2005) Clinical practice. Hirsutism. New England Journal of Medicine, 353, 2578 2588.
38. Hother-Nielsen, O. Beck-Nielsen, H. (1990) On the determination of basal glucose production rate in patients with type 2 (non-insulin-dependent) diabetes mellitus using primed-continuous 3-3H-glucose infusion. Diabetologia, 33, 603 610.
39. Hother-Nielsen, O., Mengel, A., Moller, J., Rasmussen, O., Schmitz, O. Beck-Nielsen, H. (1992) Assessment of glucose turnover rates in euglycaemic clamp studies using primed-constant [3-3H]-glucose infusion and labelled or unlabelled glucose infusates. Diabetic Medicine, 9, 840 849.
40. Hother-Nielsen, O., Henriksen, J.E., Staehr, P. Beck-Nielsen, H. (1995) Labelled glucose infusate technique in clamp studies. Is precise matching of glucose specific activity important? Endocrinology and Metabolism, 2, 275 287.
41. Ferrannini, E. (1988) The theoretical bases of indirect calorimetry: a review. Metabolism, 37, 287 301.
42. Lykkesfeldt, G., Bennett, P., Lykkesfeldt, A.E., Micic, S., Moller, S. Svenstrup, B. (1985) Abnormal androgen and oestrogen metabolism in men with steroid sulphatase deficiency and recessive X-linked ichthyosis. Clinical Endocrinology, 23, 385 393.
43. Frystyk, J., Tarnow, L., Krarup, H.T., Parving, H.H. Flyvbjerg, A. (2005) Increased serum adiponectin levels in type 1 diabetic patients with microvascular complications. Diabetologia, 48, 1911 1918.
44. Andersen, K.K., Frystyk, J., Wolthers, O.D., Heuck, C. Flyvbjerg, A. (2007) Gender differences of oligomers and total adiponectin during puberty: a cross-sectional study of 859 Danish school children. Journal of Clinical Endocrinology and Metabolism, 92, 1857 1862.
45. Altman, D.G. (1991) Practical Statistics for Medical Research. Chapman & Hall, London, 199 203.
46. Majuri, A., Santaniemi, M., Rautio, K., Kunnari, A., Vartiainen, J., Ruokonen, A., Kesaniemi, Y.A., Tapanainen, J.S., Ukkola, O. Morin-Papunen, L. (2007) Rosiglitazone treatment increases plasma levels of adiponectin and decreases levels of resistin in overweight women with PCOS: a randomized placebo-controlled study. European Journal of Endocrinology, 156, 263 269.
47. Levin, K., Hother-Nielsen, O., Henriksen, J.E. Beck-Nielsen, H. (2004) Effects of troglitazone in young first-degree relatives of patients with type 2 diabetes. Diabetes Care, 27, 148 154.
48. Dunaif, A., Xia, J., Book, C.B., Schenker, E. Tang, Z. (1995) Excessive insulin receptor serine phosphorylation in cultured fibroblasts and in skeletal muscle. A potential mechanism for insulin resistance in the polycystic ovary syndrome. Journal of Clinical Investigation, 96, 801 810.
49. Corbould, A., Kim, Y.B., Youngren, J.F., Pender, C., Kahn, B.B., Lee, A. Dunaif, A. (2005) Insulin resistance in the skeletal muscle of women with PCOS involves intrinsic and acquired defects in insulin signaling. American Journal of Physiology. Endocrinology and Metabolism, 288, E1047 E1054.
50. Book, C.B. Dunaif, A. (1999) Selective insulin resistance in the polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism, 84, 3110 3116.
51. Corbould, A., Zhao, H., Mirzoeva, S., Aird, F. Dunaif, A. (2006) Enhanced mitogenic signaling in skeletal muscle of women with polycystic ovary syndrome. Diabetes, 55, 751 759.
52. Tschritter, O., Fritsche, A., Thamer, C., Haap, M., Shirkavand, F., Rahe, S., Staiger, H., Maerker, E., Haring, H. Stumvoll, M. (2003) Plasma adiponectin concentrations predict insulin sensitivity of both glucose and lipid metabolism. Diabetes, 52, 239 243.
53. Romualdi, D., Guido, M., Ciampelli, M., Giuliani, M., Leoni, F., Perri, C. Lanzone, A. (2003) Selective effects of pioglitazone on insulin and androgen abnormalities in normo- and hyperinsulinaemic obese patients with polycystic ovary syndrome. Human Reproduction, 18, 1210 1218.
54. Brettenthaler, N., De Geyter, C., Huber, P.R. Keller, U. (2004) Effect of the insulin sensitizer pioglitazone on insulin resistance, hyperandrogenism, and ovulatory dysfunction in women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism, 89, 3835 3840.
55. Guido, M., Romualdi, D., Suriano, R., Giuliani, M., Costantini, B., Apa, R. Lanzone, A. (2004) Effect of pioglitazone treatment on the adrenal androgen response to corticotrophin in obese patients with polycystic ovary syndrome. Human Reproduction, 19, 534 539.